Drug updated on 11/10/2023
|Injection (intravenous; 50 mg/ 10 mL)
|P2Y12 platelet inhibitors
|Ongoing and Completed Studies
- Indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Product Monograph / Prescribing Information
|Kengreal (cangrelor) Prescribing Information.
|Chiesi USA, Inc., Cary, NC
Systematic Reviews / Meta-Analyses
|Safety and efficacy of cangrelor in acute stroke treated with mechanical thrombectomy: endovascular treatment of ischemic stroke registry and meta-analysis.
|American Journal of Neuroradiology
|Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta analysis.
|Cangrelor or clopidogrel in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
|Meta-analysis of the role of cangrelor for patients undergoing percutaneous coronary intervention.
|The American Journal of Cardiology
|Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety
|The Annals of pharmacotherapy
|Meta-analysis of comparison of the newer p2y12 inhibitors (oral preparation or intravenous) to clopidogrel in patients with acute coronary syndrome
|Journal of Cardiovascular Pharmacology
Clinical Practice Guidelines
|2021 ACC/AHA/SCAI guideline for coronary artery revascularization.
|Journal of the American College of Cardiology
|2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
|European Heart Journal